Drug updated on 4/16/2024

Dosage FormSolution (topical: 10%)
Drug ClassAzole antifungals
Ongoing and
Completed Studies


  • Indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Efinaconazole (Jublia) is indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes, showing significant improvement over vehicle treatments in achieving complete and mycological cures.
  • The information was derived from three studies that focused on or mentioned Jublia among other treatments for onychomycosis.
  • Compared to ciclopirox 8% lacquer and tavaborole 5% solution, efinaconazole demonstrated superior outcomes in terms of achieving complete cures with high-quality evidence supporting its effectiveness; however, it has a slightly increased risk of adverse events such as dermatitis and vesicles.
  • In comparison with oral treatments, which generally offer a greater likelihood of cure but come with higher risks requiring closer monitoring, efinaconazole presents an effective alternative, especially considering its favorable safety profile.
  • Quality-of-life scores associated with onychomycosis improved across all treatment types, including efinaconazole; women and those with fingernail involvement reported poorer initial quality-of-life scores, indicating potential subgroup considerations.
  • The choice between oral or topical treatments like efinaconazole should be individualized based on patient factors such as age, general health status, causative organism type, and number and extent of nail involvement, highlighting the importance of a personalized approach to therapy selection.

Product Monograph / Prescribing Information

Document TitleYearSource
Jublia (efinaconazole) prescribing infromation.2022Bausch Health US LLC, Bridgewater, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review.2021Journal of the American Academy of Dermatology
Topical and device-based treatments for fungal infections of the toenails (review). 2020Cochrane Database of Systematic Reviews
Antifungal drug use for onychomycosis.2019American Journal of Therapeutics

Clinical Practice Guidelines

Document TitleYearSource
Therapeutic recommendations for the treatment of toenail onychomycosis in the US. 2021Journal of Drugs in Dermatology